Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Charité - Universitätsmedizin Berlin · Helios Hospital Berlin-Buch · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
615
total citations
- FWCI
- 31.36
- Percentile
- 100%
- References
- 33
Citations per year
Authors
10Topics & keywords
Topics
Keywords
- Irinotecan
- Medicine
- Chemotherapy
- Cancer
- Phases of clinical research
- Internal medicine
- Oncology
- Oxaliplatin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.